HK1199815A1 - Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation - Google Patents
Levocetirizine and montelukast for the treatment of influenza, common cold and inflammationInfo
- Publication number
- HK1199815A1 HK1199815A1 HK15100262.4A HK15100262A HK1199815A1 HK 1199815 A1 HK1199815 A1 HK 1199815A1 HK 15100262 A HK15100262 A HK 15100262A HK 1199815 A1 HK1199815 A1 HK 1199815A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- levocetirizine
- montelukast
- influenza
- inflammation
- treatment
- Prior art date
Links
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 206010022000 influenza Diseases 0.000 title 1
- 229960001508 levocetirizine Drugs 0.000 title 1
- 229960005127 montelukast Drugs 0.000 title 1
- 201000009240 nasopharyngitis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35552010P | 2010-06-16 | 2010-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1199815A1 true HK1199815A1 (en) | 2015-07-24 |
Family
ID=45348536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100262.4A HK1199815A1 (en) | 2010-06-16 | 2013-10-17 | Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation |
Country Status (11)
Country | Link |
---|---|
US (5) | US9044479B2 (fr) |
EP (2) | EP2582373A4 (fr) |
JP (2) | JP5781606B2 (fr) |
KR (2) | KR20130050952A (fr) |
CN (2) | CN103002896A (fr) |
AU (1) | AU2011268342B2 (fr) |
CA (1) | CA2802853C (fr) |
ES (1) | ES2705244T3 (fr) |
HK (1) | HK1199815A1 (fr) |
MX (2) | MX2012014521A (fr) |
WO (1) | WO2011159821A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9044479B2 (en) | 2010-06-16 | 2015-06-02 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
EP4324479A3 (fr) | 2012-08-21 | 2024-04-24 | Sanofi Biotechnology | Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste de l'il-4r |
CN105263579B (zh) * | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
AU2014249456B2 (en) | 2013-03-13 | 2018-08-09 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
EP3308835B1 (fr) * | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Utilisation de lévocétirizine et de montélukast dans le traitement des blessures traumatiques |
MX2015011775A (es) * | 2013-03-13 | 2015-12-01 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
EP3463324A4 (fr) * | 2016-06-03 | 2020-01-29 | Irr, Inc. | Lévocétirizine et montélukast dans le traitement d'états pathologiques médiés par une exposition à des rayonnements |
WO2019004776A2 (fr) * | 2017-06-30 | 2019-01-03 | Hanmi Pharm. Co., Ltd. | Comprimé à mâcher composite comprenant de la lévocétirizine et du montélukast à stabilité et observance médicamenteuse améliorées, et son procédé de préparation |
EP3648767A4 (fr) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule |
WO2021207729A1 (fr) * | 2020-04-10 | 2021-10-14 | Mubarak Kamal Khan | Compositions et procédés de modulation du récepteur de l'ace2 |
US11844792B2 (en) * | 2020-07-10 | 2023-12-19 | Sean Downing | Treatment for severe acute respiratory illness associated with coronavirus |
KR102481517B1 (ko) * | 2021-08-30 | 2022-12-27 | 주식회사 클라시아 | 약제학적 제제 |
WO2023091107A1 (fr) * | 2021-11-22 | 2023-05-25 | Istanbul Medipol Universitesi | Préparation de nouvelles formulations médicamenteuses capables de présenter un effet antiviral et investigation de leur effet contre la covid-19 |
US20230190734A1 (en) * | 2021-12-16 | 2023-06-22 | IRR, Inc. | Levocetirizine and montelukast in the treatment of coronavirus disease and symptoms thereof |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
US5211958A (en) | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
US5147637A (en) | 1988-06-07 | 1992-09-15 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
JPH07503629A (ja) | 1991-11-14 | 1995-04-20 | アライアンス ファーマシューティカル コーポレイション | フルオロカーボンを用いた部分的液体呼吸法および装置 |
JPH09510952A (ja) | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
JP2001511134A (ja) | 1997-01-24 | 2001-08-07 | オートイミューン インク | メトトレキサートと組合せる耐性化を用いる自己免疫疾患の治療 |
WO1999032125A1 (fr) * | 1997-12-23 | 1999-07-01 | Schering Corporation | Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine |
AU2470299A (en) | 1998-01-27 | 1999-08-09 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
NZ524121A (en) * | 2000-07-28 | 2005-09-30 | Immupharm Aps | Compounds for treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
US7718198B2 (en) | 2001-06-20 | 2010-05-18 | Metaproteomics, Llc | Treatment modalities for autoimmune diseases |
RO122476B1 (ro) * | 2001-06-28 | 2009-07-30 | Ucb S.A. | Tabletă conţinând cetirizină şi pseudoefedrină |
EP1471907B1 (fr) | 2001-06-29 | 2008-07-16 | AB Science | Utilisation d'inhibiteurs de c-kit destines a traiter des maladies auto-immunes |
DE50312523D1 (de) | 2002-05-24 | 2010-04-29 | Carl-Fr Coester | Pharmazeutische wirkstoffkombination sowie deren verwendung |
US7291331B1 (en) * | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
CA2518409A1 (fr) | 2003-03-12 | 2004-09-23 | John P. Mullally | Composition et procede de traitement d'inflammations par reduction des proteines c-reactives |
US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
ZA200702335B (en) | 2004-10-05 | 2009-05-27 | Genentech Inc | Method for treating vasculitis |
FR2881823B1 (fr) | 2005-02-08 | 2007-03-16 | Siemens Vdo Automotive Sas | Utilisation de la magneto-impedance sur un capteur de position sans contact et capteur correspondant |
US20070244128A1 (en) * | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
JP5107933B2 (ja) | 2005-12-21 | 2012-12-26 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 炎症性疾患の治療に使用する、抗コリン作用薬類、β2−アドレナリン受容体のアゴニスト類、抗ロイコトリエン(ロイコトリエン受容体のアンタゴニスト)類、グルココルチコイド類および/またはPDE4阻害剤類の新規配合薬 |
US7589076B2 (en) | 2006-05-18 | 2009-09-15 | Pgx Health, Llc | Substituted aryl piperidinylalkynyladenosines as A2AR agonists |
EP2559434A3 (fr) | 2007-02-12 | 2013-05-29 | Mike Nicolaou | Traitement de la BPCO avec un inhibiteur de l'histidine décarboxylase seul ou combiné à un composé anti-H1 ou à un antagoniste du récepteur des leucotriènes |
EP2129683A4 (fr) | 2007-02-26 | 2011-01-05 | Ironwood Pharmaceuticals Inc | Procedes et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles |
WO2009022327A2 (fr) | 2007-08-15 | 2009-02-19 | Chemagis Ltd. | Nouveau procédé de préparation de lévocétirizine de pureté élevée et de ses sels |
CA2703672A1 (fr) | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Compositions et procedes pour moduler la transduction de signal intracellulaire vehicule par membrane cellulaire |
US20100305080A1 (en) | 2007-10-25 | 2010-12-02 | O'shea Paul | Novel Crystalline Salts of Montelukast |
US20090227018A1 (en) * | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
PL2403845T3 (pl) | 2009-03-02 | 2014-09-30 | Generics Uk Ltd | Ulepszony sposób |
WO2010107404A1 (fr) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Combinaisons pharmaceutiques stables |
US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
BR112012018913A2 (pt) | 2010-01-28 | 2017-06-20 | Merck Sharp & Dohme | "composição farmacêutica, e, uso da composição" |
US9044479B2 (en) | 2010-06-16 | 2015-06-02 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
JP2013535456A (ja) | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
TR201009398A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Fiziksel özellikleri geliştirilmiş tablet formülasyonları |
EP2658538A2 (fr) | 2010-12-30 | 2013-11-06 | M.D. Ziv Harish | Préparations utilisables en vue de la prévention et/ou du traitement topique de symptômes allergiques oraux provoqués par un contact oral avec des fruits et/ou des légumes |
MX2013011888A (es) | 2011-04-13 | 2014-02-27 | Revalesio Corp | Composiciones y metodos para inhibir y/o modular las celulas-t efectoras involucradas en la enfermedad neurodegenerativa inflamatoria. |
EP2520292A1 (fr) | 2011-05-06 | 2012-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Utilisation de spirangiens pour le traitement ou la prévention des troubles liés à IL-8 ou IL-6 |
KR20130009553A (ko) | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
MX336224B (es) | 2011-07-26 | 2016-01-12 | Boehringer Ingelheim Int | Quinolinas sustituidas y su uso como medicamentos. |
CN102895661A (zh) | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
CN103505731A (zh) | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
US20150322049A1 (en) | 2012-12-13 | 2015-11-12 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
AU2014249456B2 (en) | 2013-03-13 | 2018-08-09 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
MX2015011775A (es) | 2013-03-13 | 2015-12-01 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. |
CN105263579B (zh) | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
EP3308835B1 (fr) | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Utilisation de lévocétirizine et de montélukast dans le traitement des blessures traumatiques |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
EP3463324A4 (fr) | 2016-06-03 | 2020-01-29 | Irr, Inc. | Lévocétirizine et montélukast dans le traitement d'états pathologiques médiés par une exposition à des rayonnements |
-
2011
- 2011-06-15 US US13/704,589 patent/US9044479B2/en active Active
- 2011-06-15 EP EP11796386.8A patent/EP2582373A4/fr not_active Withdrawn
- 2011-06-15 AU AU2011268342A patent/AU2011268342B2/en active Active
- 2011-06-15 KR KR1020137001049A patent/KR20130050952A/ko active Application Filing
- 2011-06-15 WO PCT/US2011/040562 patent/WO2011159821A1/fr active Application Filing
- 2011-06-15 ES ES14174035T patent/ES2705244T3/es active Active
- 2011-06-15 EP EP14174035.7A patent/EP2799071B1/fr active Active
- 2011-06-15 MX MX2012014521A patent/MX2012014521A/es active IP Right Grant
- 2011-06-15 CN CN2011800293238A patent/CN103002896A/zh active Pending
- 2011-06-15 JP JP2013515486A patent/JP5781606B2/ja active Active
- 2011-06-15 CA CA2802853A patent/CA2802853C/fr active Active
- 2011-06-15 MX MX2015009169A patent/MX352824B/es unknown
- 2011-06-15 CN CN201710268827.4A patent/CN107308161A/zh active Pending
- 2011-06-15 KR KR1020157007510A patent/KR101801864B1/ko active IP Right Grant
-
2013
- 2013-10-17 HK HK15100262.4A patent/HK1199815A1/xx unknown
-
2015
- 2015-05-05 US US14/704,444 patent/US20150231133A1/en not_active Abandoned
- 2015-07-14 JP JP2015140300A patent/JP2015180701A/ja active Pending
- 2015-12-18 US US14/974,930 patent/US10537568B2/en active Active
-
2019
- 2019-04-11 US US16/382,077 patent/US20190298714A1/en not_active Abandoned
-
2020
- 2020-06-04 US US16/893,229 patent/US20200323843A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2802853C (fr) | 2016-07-26 |
KR20130050952A (ko) | 2013-05-16 |
US20160175301A1 (en) | 2016-06-23 |
EP2799071B1 (fr) | 2018-10-17 |
JP2013528654A (ja) | 2013-07-11 |
EP2582373A4 (fr) | 2013-10-30 |
JP5781606B2 (ja) | 2015-09-24 |
EP2799071A1 (fr) | 2014-11-05 |
MX352824B (es) | 2017-12-11 |
AU2011268342B2 (en) | 2014-12-04 |
CN103002896A (zh) | 2013-03-27 |
KR20150038736A (ko) | 2015-04-08 |
US20190298714A1 (en) | 2019-10-03 |
US10537568B2 (en) | 2020-01-21 |
US9044479B2 (en) | 2015-06-02 |
CN107308161A (zh) | 2017-11-03 |
EP2582373A1 (fr) | 2013-04-24 |
CA2802853A1 (fr) | 2011-12-22 |
US20200323843A1 (en) | 2020-10-15 |
AU2011268342A1 (en) | 2013-01-31 |
US20130085124A1 (en) | 2013-04-04 |
ES2705244T3 (es) | 2019-03-22 |
MX2012014521A (es) | 2013-05-20 |
US20150231133A1 (en) | 2015-08-20 |
KR101801864B1 (ko) | 2017-11-27 |
WO2011159821A1 (fr) | 2011-12-22 |
JP2015180701A (ja) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1199815A1 (en) | Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation | |
HRP20181364T8 (hr) | Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci | |
HK1203359A1 (en) | Enzyme compositions and use thereof for wound healing | |
HRP20151041T1 (hr) | Šprica i spremnik s dvostrukom komorom i šprica napunjena aripiprazolom | |
EP2651496A4 (fr) | Dispositifs, systèmes et méthodes pour le traitement de troubles médicaux | |
GB2503066B (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
EP2866830A4 (fr) | Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l'inhibition de l'inflammation | |
IL236226A0 (en) | Medicinal or prophylactic agent for mild cognitive impairment | |
HK1211221A1 (en) | Formulations for the treatment and prevention of obesity | |
HK1209639A1 (en) | Gpbp-1 inhibition and its therapeutic use gpbp-1 | |
HK1188565A1 (en) | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | |
GB201117269D0 (en) | Peptoids for the phrophlyactic and therapeutic clearance of bacteria | |
AU2012903508A0 (en) | Breast-protective orthosis and use thereof | |
AU2012901404A0 (en) | Patient registration and consent kiosk | |
GB201116165D0 (en) | Metatronia therapy-a healing modality, using the eneriges and connections of archangel metatron | |
AU2010901717A0 (en) | Cold treatment |